Dive into the archives.
- Hot off the ECTRIMS Press…Alemtuzumab Shows Lasting Benefits in RRMS
(RTTNews) - Friday, biotechnology company Genzyme Corp. said that four-year follow-up data from its completed Phase 2 multiple sclerosis trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab. The accumulated four-year efficacy and safety data [...]
- Hot off the ECTRIMS Press…Fewer Injection Site Reactions with Avonex
CAMBRIDGE, MA – Sept. 11, 2009 – Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon beta-1a IM) reported significantly fewer injection site reactions (ISRs) compared to patients on Betaferon (interferon beta-1b), Copaxone (glatiramer Acetate) or Rebif (interferon beta-1a). [...]
- Hot off the ENS Press…Rebif Autoinject Improves SC Delivery
MILAN, Italy June 26, 2009 A new electronic, multidose, autoinjection device improves subcutaneous delivery of interferon beta (IFNB)-1a in patients with relapsing multiple sclerosis (MS), according to a study presented here at the 19th Meeting of the European Neurological Society (ENS2009). Virginia Devonshire, MD, Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, [...]
